The Rescue Inhaler Market is estimated to be valued at US$ 15.54 Bn in 2023 and is expected to exhibit a CAGR of 8.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:- Rescue inhalers, also known as quick-relief or reliever inhalers, provide fast relief from symptoms of asthma and chronic obstructive pulmonary disease (COPD) like wheezing, coughing, breathlessness and chest tightness. The most commonly used rescue inhalers contain short-acting beta2-agonists (SABAs) such as albuterol/salbutamol, which work directly on the airways to relax their muscles and widen the breathing passages. They are available both as metered dose inhalers (MDIs) and dry powder inhalers (DPIs). Market Dynamics:- The Rescue Inhaler Market is expected to witness significant growth over the forecast period owing to rising prevalence of asthma and COPD globally. According to WHO, around 262 million people suffer from asthma worldwide. Likewise, over 384 million people have COPD globally according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD). This high disease prevalence is creating a huge demand for rescue inhalers for quick relief of symptoms. Furthermore, technological advancements in inhaler drug delivery devices aimed at improving efficacy, reducing side effects and strengthening doctor-patient compliance are also fueling market growth. For instance, smart connected inhalers allow physicians to monitor patients' medication use histories remotely and provide timely guidance for better management of symptoms. Segment Analysis:- The rescue inhaler market is dominated by short-acting beta2-agonists (SABA) segment, accounting for over 70% market share. SABA offers fast and effective relief for acute asthma attacks and provides essential bronchodilation within 3-5 minutes of inhalation. They are prescribed as the first line treatment for mild and intermittent asthma symptoms. PEST Analysis:-
The global rescue inhaler market is expected to witness high growth, exhibiting CAGR of 8.7% over the forecast period, due to increasing geriatric population suffering from respiratory diseases. The North American region currently dominates the market due to sedentary lifestyle and growing pollution levels. The North American region is expected to retain its dominance in the global rescue inhaler market over the forecast period. This is attributed to high prevalence of asthma across the US and Canada owing to genetic predisposition, growing environmental pollution levels and rising healthcare expenditure in the region. Key players operating in the rescue inhaler market are GlaxoSmithKline, Teva Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Pfizer, Sunovion Pharmaceuticals, Roche. GlaxoSmithKline leads the market with its Ventolin and Flovent inhalers. Teva Pharmaceuticals markets Proventil HFA and Brovana rescue inhalers. Read More - https://www.newsstatix.com/rescue-inhaler-market-share-and-trends-analysis/
0 Comments
Leave a Reply. |